Targeted Medical Pharma Signs Agreement to Assign Certain Accounts Receivables to Cambridge Medical Funding Group

Los Angeles, November 27, 2012Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a specialty pharmaceutical company that develops and sells prescription medical foods to physicians and pharmacies for the treatment of chronic disease, today reported the completion of an agreement under which certain accounts receivables will be assigned to New Jersey-based Cambridge Medical Funding Group, LLC (CMFG).

Under the terms of the agreement, medical providers who purchase products from Targeted Medical Pharma will have the option to assign certain accounts receivables from California Workers’ Compensation benefit claims to CMFG at a discounted rate.

“This agreement permits Targeted Medical Pharma to more quickly collect outstanding amounts owed to the company by physicians who will purchase our products, providing us with more opportunities to accelerate growth because of the improved time-to-collection,” said William Shell, M.D., CEO of Targeted Medical Pharma. “Physicians also will benefit from the reduced time spent on the billing and collection process and avoid lengthy delays in workers’ compensation payer reimbursements.”

About Cambridge Medical Funding Group, LLC

Based in Glen Rock, New Jersey, Cambridge Medical Funding Group provides specialized finance solutions to hospitals, surgical centers and medical providers, purchasing receivables and providing guaranteed upfront payments to these providers.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians and pharmacies for the treatment of chronic disease, including pain syndromes, obesity, sleep and cognitive disorders. The company manufactures nine proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are currently sold in the United States, Japan, and the Middle East. Targeted Medical Pharma also provides billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release about an agreement with Medical Funding Group, LLC may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #

Targeted Medical Pharma to Present at Upcoming Investor Conferences

Los Angeles, November 5, 2012 – Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, today announced that members of its executive team are scheduled to present and conduct one-on-one meetings at the following investor conferences:

  • Wednesday, November 7, 2012
    14th Annual SoCal Bio Conference & Exhibition

    Omni Hotel – 251 South Olive Street, Los Angeles, CA
    2:00 p.m. Eastern Time (11:00 a.m. Pacific Time)
  • Thursday, November 29, 2012
    New York Society of Security Analysts’ (NYSSA) 16th Annual Investing in Life Sciences Conference

    NYSSA Conference Facilities – 1540 Broadway, New York, NY
    1:30 p.m. Eastern Time (10:30 a.m. Pacific Time)

A live webcast of the NYSSA presentation will be available at the company’s website at www.tmedpharma.com.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including pain syndromes, obesity, sleep and cognitive disorders. The company manufactures nine proprietary prescription only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are currently sold in the United States and Japan. Targeted Medical Pharma also provides billing and collection services on behalf of dispensing physicians.

Click here to download press release.

Use of Medical Food Theramine® Found to be Safer and Less Costly Than NSAIDs for Pain Treatment in Elderly Patients

Pharmacoeconomic Analysis Examines the Additional Cost to Prevent
Gastrointestinal Side Effects and Complications

Theramine® Lowered C-reactive protein (CRP) in Clinical Trial

Los Angeles, October 23, 2012 – Medical food Theramine® should be the preferred treatment for pain when compared to NSAIDs (non-steroidal anti-inflammatory drugs) in elderly patients 65 years and older, according to a pharmacoeconomic analysis conducted by Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM) published in the May issue of the Journal of Pharmacy Research.

The scientific economic paper, “Theramine (A Medical Food) Versus Non-Steroidal Anti Inflammatory Agents in Elderly Patients: A Pharmacoeconomic Analysis,” examines the additional cost burden of the strategies to prevent gastrointestinal side effects and complications. A PDF of the full pharmacoeconomic analysis can be viewed by visiting http://bit.ly/TheramineVsNSAIDs.

“Non-steroidal anti-inflammatory drugs are the leading cause of drug induced morbidity and mortality in the United States,” said David S. Silver, M.D., corresponding author of the pharmacoeconomic analysis, and executive VP of medical and scientific affairs at Targeted Medical Pharma, Inc., which develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities. “Gastrointestinal hemorrhage is the most common concern when using NSAIDs, along with hypertension, edema, renal complication and cardiovascular risk, all which occur at higher rates in elderly patients. Patients over the age of 65 with concomitant medications and disease states are the most likely to suffer serious consequence side effects of NSAIDs.”

The analysis found that the actual cost of using Theramine is considerably lower when compared to the total impact of NSAIDs. Excluding the treatment for hepatic, renal and cardiovascular side effects, the annual cost of generic NSAIDs per 100 pain and inflammation patients is $241,500, compared to an annual cost of $211,200 per 100 patients using Theramine.

“Theramine is a prescription only medical food that is used to treat fibromyalgia, acute and chronic neuropathic or inflammatory pain without risk of gastrointestinal or other side effects,” added Dr. Silver. “The higher acquisition costs for Theramine are offset by the reduction in side effects and need for testing and other protective medications in patients over the age of sixty-five taking NSAIDs, making Theramine a preferred choice over non-steroidal anti-inflammatory drugs in elderly patients.”

Methodology

Safety and efficacy data were derived from two large double-blind controlled trials that compared Theramine to low dose naproxen and ibuprofen, as well as other industry published literature. A total of 256 patients across 12 independent sites were randomized for treatment to receive Theramine alone (two capsules twice daily), NSAID or a combination of both. In both studies, Theramine showed statistically significantly greater pain relief than either naproxen at 250mg daily or ibuprofen at 400mg daily. The studies also revealed that Theramine, when administered as a standalone medication and in combination with an NSAID, lowered a statistically significant amount of CRP (C-reactive protein), while an increased CRP level was seen in the naproxen and ibuprofen groups. No side effects from Theramine were reported in the trials and observational reporting after 38,000,000 doses of Theramine showed no gastrointestinal bleeds.

Risk data and rates of gastrointestinal bleeding, morbidity and mortality data were derived from the Medicare database and peer reviewed literature. Medication acquisition costs were determined based on listed average wholesale pricing (AWP). Procedural and hospitalization rates were obtained from the Medicare fee schedule. A cost per life saved analysis was not performed since there is no incremental overall cost increase to the use of Theramine.

Full citation:

“Theramine (A Medical Food) Versus Non-Steroidal Anti Inflammatory Agents in Elderly Patients: A Pharmacoeconomic Analysis.” David S. Silver, M.D.; Elizabeth H. Charuvastra, RN; Lawrence May, M.D.; Stephanie L. Pavlik, CRA; William E. Shell, M.D. Journal of Pharmacy Research (Volume 5, Issue 5); Published online: May 2012.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma’s medical foods are amino acid based, FDA-regulated medications specially formulated to meet the body’s increased nutritional requirements of disease. They are a safe and effective option for treating pain syndromes, sleep disorders and obesity without harmful side effects. Physician Therapeutics’ medical food products are available by prescription only and must be administered under the ongoing supervision of a physician.

About Targeted Medical Pharma’s Medical Foods

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including pain syndromes, obesity, and sleep and cognitive disorders. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and Japan. The company manufactures nine proprietary medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

Click here to download press release.

Targeted Medical Pharma Commences Public Trading of Its Securities

Shares Begin Trading Over-the-Counter Under Symbol “TRGM”

Los Angeles, October, 12, 2012 – Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, today announced that effective today, its common shares will be trading over-the-counter under the symbol “TRGM” on OTC Market Group’s OTCQB market and the Over-the-Counter Bulletin Board (OTCBB). The company’s publicly traded status follows FINRA’s approval of its 15c2-11 filing.

“We are very excited to begin the next phase of the evolution of our company,” said William Shell, M.D., chief executive officer of Targeted Medical Pharma. “With medical foods gaining wider acceptance among physicians and patients, we believe the company is positioned to enjoy further growth, as we increase marketing efforts for our nine proprietary medical food products and focus on the development of new products that address large patient populations.”

Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc., is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including pain syndromes, obesity, and sleep and cognitive disorders. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and Japan. The company manufactures nine proprietary medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medications and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

Click here to download press release.

####

Targeted Medical Pharma Issues Letter to Shareholders

Los Angeles, July 17, 2012 –Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, today issued the following letter to shareholders from its Chairman and Chief Executive Officer and Chief Scientific Officer, William Shell, M.D.

Dear Fellow Shareholders:

If one word can best characterize the past year for me and for Targeted Medical Pharma, that word would be change.

It has been a fast-paced journey for all of us, marked by substantial growth that places our company on the cusp of formidable transformation.

There was great progress positioning us for the introduction of promising new products, having filed multiple new patents, completing clinical trials of a treatment for Post-Traumatic Stress Disorder (PTSD) and developing an advanced obesity management system. As we enter the second half of 2012, our team is excited about the research that is now well underway on a technology, believed to be the first of its kind, for stem cell stimulation via an oral administration.

As of this writing, our employee count has grown to 68 full time employees, with more than 40 direct and indirect sales representatives in our own sales force and those of our distributors. Importantly, we also strengthened our senior management team. In November, we were privileged that David Silver, M.D., an Associate Professor at UCLA School of Medicine, joined the Company as our Executive Vice President for Medical and Scientific Affairs. Dr. Silver brings tremendous expertise to Targeted Medical Pharma, and I know he will be instrumental, along with our talented team, in fostering our future growth and development.

Additionally, Ron Rudolph joined us as Chief Financial Officer, Douglas Gintz came aboard as Chief Technology and Information Officer, and Dr. Lynette Gebler joined us to further develop our claims collection process. Amir Blachman was promoted to Vice President of Strategy and Operations and Corporate Secretary. More recently, we appointed a National Sales Director, Darion Petty, to lead the expansion of our footprint throughout the United States and we added a Senior Medical Science Liaison, Dr. Fred McCall-Perez, to expand our education processes to physicians, key opinion leaders and other healthcare providers.

In Memoriam

Amid the positive change and momentum, we were deeply saddened in September 2011 with the passing of Elizabeth Charuvastra, our co-founder, Executive Chairman, and my wife

Liz was steadfastly dedicated to improving patient care and quality of life. She was unshakeable in her belief that we must better understand the safety and efficacy of pharmaceutical agents.

Liz’s contributions improved, and will continue to improve, the lives of tens of thousands of people. We miss Liz deeply but are blessed to continue the work that was shaped by her legacy of caring and by her medical insights.

Financial Overview and Plans for Public Trading of our Stock

With all the moving parts and a wonderful market opportunity before us, we also effected change in our financial structure and in our plans to soon become a publicly traded company.

In preparation for public trading of our securities, and to more appropriately align our financial reporting with the underlying economics of our business, we changed the Company’s revenue recognition policy, which in turn resulted in a restatement of our financials and net operating losses for 2010 and 2011.

On the positive side of the restatement, although more than $30 million in receivables from our physician clients and distributors could no longer be deemed revenue until payment is received, our physician clients and distributors remain contractually obligated to pay those amounts and those amounts will be recorded as revenue when collected. Backing up these receivables are outstanding insurance claims in excess of $50 million in claims payments. The billing and collection process is being managed by our subsidiary, Complete Claims Processing, Inc., on behalf of physician customers.

The new revenue recognition policy and restatement provided the basis for filing an amended 2010 tax return in May 2012. The restatement also resulted in the conversion of a $4.3 million tax liability to a tax refund receivable in excess of $800,000 and long-term carry-forward losses in excess of $4 million. As part of the change, albeit positive to our future, a “going concern” notation, which we believe is temporary, was included in the auditor’s report on our fiscal year 2011 financial statements.

In part, the revenue recognition policy change and restatement of our financial statements led us to change our plans with regard to our methodology for creating a public trading market in our securities, and on June 5, 2012, we withdrew our registration statement (Form S-1), which related to our initial public offering of common stock and a resale of common stock by existing stockholders, which was pending with the Securities and Exchange Commission. We originally planned to raise up to $40 million in an underwritten public offering. However, since that amount would have resulted in substantial dilution of the current shareholders and is far in excess of our immediate requirements, we are instead in the process of preparing our common stock for quotation on the OTC Bulletin Board. A one-year seasoning on this trading platform will allow us, without diluting our shareholders, to apply for listing on a national securities exchange, namely Nasdaq or the New York Stock Exchange, which is fully our intention, assuming we meet all other listing standards at that time. We are optimistic that our common stock will be quoted on the OTC Bulletin Board before the close of the current quarter.

With complex structural matters now essentially behind us, we are considering alternate financing strategies to provide capital for future growth, including securing debt financing and selling a portion of our accounts receivable balance. The sale of contractual accounts receivable will raise cash and generate revenue. We currently are in active discussions to complete these components of the short-term funding strategy and intend to raise between $5 million and $10 million as part of this process.

Growth Opportunities Ahead

The year ahead looks stronger than ever.

We plan to grow our workers’ compensation client development and improve its collection process, and we already have embarked on substantial growth plans for our private insurance (PPO) market, which now has clients in 19 states.

With baby boomers now reaching Medicare eligibility, their growing numbers also provide us with a solid opportunity. There are currently approximately 44 million patients who receive medications under the Medicare Part D program. We are selling into this market, as the use of medical foods in clinical practice is growing due to wider acceptance among physicians and patients. We still must follow a complex collection process in Part D Medicare that is related to the definition of a covered drug. On February 17, 2012, the Center for Medicare and Medicaid Services published in the Federal Register a definition of a covered drug that is favorable to our efforts to expand our Medicare Part D business. That was great news for us.

In what we also believe to be a strong growth opportunity, during the past year we entered the skilled nursing home segment and already have contracted with a major provider of medications to these facilities. Test dispenses have occurred and the billing process is being initiated for multiple reimbursement methods.

As thousands of U.S. troops return from the Middle East, we expect to play an important role in treating PTSD with the successful completion of a clinical trial and anticipation of entering this market later in 2012. Protocols also are being developed by the Company in cooperation with the U.S. Joint Forces Command to examine the utility of the pain product Theramine® in the military community. These new business segments should significantly reduce time to collection, as compared to our workers’ compensation business.

Additionally, we have completed the initial evaluation of a medical food product for the treatment of asthma, particularly in children, in cooperation with a new collaborative partner. A placebo-controlled trial to test this product is in the final stages of design, and the project will be co-funded by the Company and our collaborating partner. We also have developed an advanced obesity management system, which is now undergoing initial tests.

Oral Stem Cell Stimulation System

As I mentioned at the beginning of this letter, we are particularly excited about the patents filed earlier this year on the oral stem cell stimulation system—a technology that we believe may be the first stem cell system using stimulation of progenitor stem cells within the body via an orally administered medication. This system would eliminate the need to harvest cells from the body, externally culture the cells and subsequently reintroduce them into the body.

Clinical trials were initiated in February to test a red blood cell stimulating system, a neuron regeneration and insulin method, again all via oral administration, with a focus on chronic disease states such as kidney disease, AIDS, diabetes mellitus and chronic arthritis, which are all characterized by reduced red blood cell concentrations.

We expect that the products will be developed as medical foods, with each ingredient generally recognized as safe under the FDA’s Generally Recognized as Safe (GRAS) guidelines.

A Promising Future

Targeted Medical Pharma clearly has undergone solid growth and change. We have overcome some timing setbacks and, at the same time, positioned ourselves for a bright future.

On behalf of our Board of Directors and management team, I extend deep gratitude and thanks for your patience and continued support.

I hope you will be able to join us at our annual shareholders’ meeting on August 6th, 2012, beginning at 11:00 a.m., at the Palomar Hotel near UCLA in Westwood, California. You will be receiving proxy materials and detailed information concerning the annual meeting shortly in the mail.

Sincerely,

William E. Shell, M.D.
Chief Executive Officer

Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including pain syndromes, obesity, and sleep and cognitive disorders. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and Japan. The company manufactures nine proprietary medical food products, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

Click here to download press release.

Safe Harbor Statement
This press release, including the letter to shareholders, may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Clinical Trial Shows Sentra PM® Improves Quality of Sleep

Los Angeles, May 2, 2012 – Physician Therapeutics, Inc., a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that  manufactures and distributes specialty pharmaceuticals to physicians, pharmacies and skilled nursing facilities, published results from a clinical trial of the proprietary medical food Sentra PM.  This trial demonstrated improved sleep latency and improved nighttime parasympathetic nervous system activity as a standalone medication or used in conjunction with a low dose of Trazadone. The results of this study have been published in the May issue of the Journal of Central Nervous System Disease (http://bit.ly/SentraPM_Study). 

“The study results indicate that medical foods used as a standalone medication or in conjunction with low dose pharmaceuticals can improve clinical outcomes and potentially reduce the negative side effects associated with the high dose pharmaceutical agents,” said David Silver, M.D., co-author of the study and executive vice president of medical and scientific affairs at Targeted Medical Pharma, Inc.  “Patients with sleep disorders have been shown to have reduced blood levels of serotonin and 5-hydroxyptophan.  Sentra PM provides the amino acids that are precursors to the neurotransmitters serotonin and acetylcholine, meeting the body’s increased nutritional requirements of tryptophan, choline and GABA, a common trait in sleep disorders.” 

The double-blind, four-arm, placebo-controlled study included 111 patients across 12 independent sites that were randomized for treatment with Sentra PM alone, Sentra PM with Trazadone, Trazadone alone and a placebo alone.  Results showed improvement in sleep latency for both Sentra PM and the combination of Sentra PM with Trazodone (-41 and -56 minutes, p<0.001).  Additionally, there was a statistically significant improvement in the quality of sleep for the amino acid formulation Sentra PM and the combination of Sentra PM with Trazodone (3.86 and 6.48 Likert units on a 10 point scale, p<0.001).  The study also found an activation of circadian activity at night in the medical food and combination groups while there was no change in parasympathetic activity in either the placebo or Trazodone group. 

In the study, which was completed in 2009, subjects underwent baseline screening, informed consent and an initial sleep questionnaire.  After 14 days subjects received a second evaluation by questionnaire.  At baseline and day 14, 24-hour ECG recordings were given to subjects that were analyzed in the frequency domain of heart rate variability. The specific high frequency parasympathetic autonomic nervous system activity also was analyzed.  The primary endpoints were sleep latency and parasympathetic autonomic nervous system improvement in sleeping hours. These data indicate that a medical food is an effective treatment for sleep disorders to potentially addictive sleep aids that have significant side effects.

Full citation:

Sentra PM (A Medical Food) and Trazodone in the Management of Sleep Disorders.”  William E. Shell MD, Elizabeth Charuvastra RN, Lawrence May MD, Debbie Bullias BS CRC CRA, Stephanie Pavlik CRA, David S. Silver MD.   Journal of Central Nervous System Disease; Published online: April, 2012. 

About Targeted Medical Pharma, Inc.  

Physician Therapeutics is a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of pain syndromes, obesity, sleep and cognitive disorders.  Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and Japan. The company manufactures nine proprietary medical food products, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

Physician Therapeutics to Exhibit April 23-26, 2012 in San Diego, CA

Physician Therapeutics, a division of Targeted Medical Pharma Inc. will be exhibiting at the Freedom and Recovery, Integrated Mental Health and Addiction Treatment Conference for serivce memebers and first responders, April 23-26, 2012 at the Hotel del Coronado in San Diego, CA. The exhibit will feature updated clinical data regarding the nutritional management of PTSD and Gulf War Illness as well multimodal nonaddicitive treatment options for pain syndromes.

Targeted Medical Pharma Awarded $733,429.00 in Qualifying New Therapeutic Discovery Grants

Grants Cover Theramine® , Sentra PM®, Sentra AM® and GABAdone®

Los Angeles, CA, Nov. 1, 2010 /Targeted Medical Pharma Inc. a Specialty Pharma company developing proprietary medical food products distributed through subsidiary Physician Therapeutics announced it has been awarded $733,429.00 in government grants. Under the recently enacted Patient Protection and Affordable Care Act, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed significant potential in producing new and cost-saving therapies, support job growth and increase U.S. competitiveness. Grants were awarded through a competitive application process supervised by the National Institutes of Health. All three of the Company’s applications were awarded. The first involved the reduction of gastrointestinal hemorrhage by Theramine associated with treatment of back pain syndromes. The second involves reduction of the side effects associated with sleep disorders in the elderly with Sentra PM and GABAdone, and the third addresses a safe and effective treatment for symptoms of Gulf War Illness with Sentra PM and Sentra AM. The Company will be able to expand the growth of these and other innovative products with these funds.

Download Press Release

Physician Therapeutics Clinical Trial Update

In January of 2009 Physician Therapeutics, a wholly owned subsidiary of Targeted Medical Pharma Inc.,  initiated A Double Blind randomized controlled trial of single dose Naproxen and an amino acid Medical Food Theramine for the treatment of low back pain. Using 10 national sites over a 28 day period, this study consisted of 127 patients with established back pain. The trial concluded in June of 2009, and the study will be published by the American Journal of Therapeutics in November 2010.